Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Neurobiological Technologies
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00300196CT.gov ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke | — | Terminated | — | — | — |
NCT00141011CT.gov Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke | — | Terminated | — | — | — |
NCT00343174CT.gov Intravenous Ancrod for the Treatment of Acute Ischemic Stroke Within 6 Hours After Onset of Symptoms | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Infarction
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ancrod (this asset) | Neurobiological Technologies | P3 | CC · 43 |
| Aspirin | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| Alteplase | Nippon Medical School | P4 | BB |
| 3-N-BUTYLPHTHALIDE | Qianfoshan Hospital | P4 | BB |
| Warfarin | Assistance Publique - Hôpitaux de Paris | P3 | BB |
| Eptifibatide | Arthur Pancioli | P2 | B |
| Fluoxetine | University Health Network, Toronto | P2 | B |
| Cerebrolysin | University Hospital Sestre Milosrdnice | Early P1 | C |
| Diterpene Ginkgolides Meglumine | Dongzhimen Hospital, Beijing | N/A | D |
+4 more in the Brain Infarction cohort
Other indications for Ancrod
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Brain Ischemia | — | P3 | CC · 43 |
| Stroke Disorder | — | P3 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ancrod in Brain Infarction. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ancrod-brain-infarction
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →